10-Q Filing

ARROWHEAD PHARMACEUTICALS, INC. CIK: 879407 Q1 2018

Filing Information

Form Type	10-Q
Accession Number	`0001564590-18-001768`
Period End Date	20171231
Filing Date	20180209
Fiscal Year	2018
Fiscal Period	Q1
XBRL Instance	arwr-20171231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 74 Income Statement 35 Cash Flow Statement 49 Stockholders Equity 10

Balance Sheet 74 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	145.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	145.00M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	74.79M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	74.92M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$102.11M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$24.84M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$11.53M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$85.37M	USD	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$149.93K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	74.92M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	74.79M	shares	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$67.80K	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$867.36K	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$651.24K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$1.36M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$1.60M	USD	Point-in-time
Short term investments	`HeldToMaturitySecuritiesCurrent`	$40.77M	USD	Point-in-time
Short term investments	`HeldToMaturitySecuritiesCurrent`	$39.17M	USD	Point-in-time
TOTAL CURRENT ASSETS	`AssetsCurrent`	$53.11M	USD	Point-in-time
TOTAL CURRENT ASSETS	`AssetsCurrent`	$67.90M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$14.93M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$15.51M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$20.04M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$20.46M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$141.92K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$141.92K	USD	Point-in-time
TOTAL ASSETS	`Assets`	$88.22M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$104.02M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$4.08M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$5.71M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$3.48M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$4.56M	USD	Point-in-time
Accrued payroll and benefits	`EmployeeRelatedLiabilitiesCurrent`	$1.94M	USD	Point-in-time
Accrued payroll and benefits	`EmployeeRelatedLiabilitiesCurrent`	$3.40M	USD	Point-in-time
Deferred rent	`DeferredRentCreditCurrent`	$440.58K	USD	Point-in-time
Deferred rent	`DeferredRentCreditCurrent`	$440.58K	USD	Point-in-time
Deferred revenue	`DeferredRevenueCurrent`	$1.88M	USD	Point-in-time
Deferred revenue	`DeferredRevenueCurrent`	$5.27M	USD	Point-in-time
Derivative liabilities	`DerivativeLiabilitiesCurrent`	$20.45K	USD	Point-in-time
Derivative liabilities	`DerivativeLiabilitiesCurrent`	$695.11K	USD	Point-in-time
Note Payable	`NotesPayableCurrent`	$212.23K	USD	Point-in-time
Note Payable	`NotesPayableCurrent`	$208.51K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$46.41K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$46.41K	USD	Point-in-time
TOTAL CURRENT LIABILITIES	`LiabilitiesCurrent`	$13.72M	USD	Point-in-time
TOTAL CURRENT LIABILITIES	`LiabilitiesCurrent`	$18.70M	USD	Point-in-time
Deferred rent, net of current portion	`DeferredRentCreditNoncurrent`	$1.93M	USD	Point-in-time
Deferred rent, net of current portion	`DeferredRentCreditNoncurrent`	$1.83M	USD	Point-in-time
Note Payable, net of current portion	`LongTermNotesPayable`	$2.33M	USD	Point-in-time
Note Payable, net of current portion	`LongTermNotesPayable`	$2.27M	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$200.00K	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$200.00K	USD	Point-in-time
TOTAL LONG-TERM LIABILITIES	`LiabilitiesNoncurrent`	$4.30M	USD	Point-in-time
TOTAL LONG-TERM LIABILITIES	`LiabilitiesNoncurrent`	$4.45M	USD	Point-in-time
Commitments and contingencies (Note 7)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 7)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.001 par value; 145,000,000 shares authorized; 74,917,876 and 74,785,426 shares issued and outstanding as of December 31, 2017 and September 30, 2017, respectively	`CommonStockValue`	$167.16K	USD	Point-in-time
Common stock, $0.001 par value; 145,000,000 shares authorized; 74,917,876 and 74,785,426 shares issued and outstanding as of December 31, 2017 and September 30, 2017, respectively	`CommonStockValue`	$167.29K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$514.04M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$516.58M	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$23.70K	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$33.23K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-432.82M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-446.01M	USD	Point-in-time
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity	`StockholdersEquity`	$81.42M	USD	Point-in-time
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity	`StockholdersEquity`	$70.75M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$-555.19K	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$-555.19K	USD	Point-in-time
TOTAL STOCKHOLDERS EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$80.87M	USD	Point-in-time
TOTAL STOCKHOLDERS EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$70.20M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$104.02M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$88.22M	USD	Point-in-time

Income Statement 35 line items

Line Item	Tag	Value	Unit	Period
REVENUE	`Revenues`	$4.37M	USD	1 Quarter
REVENUE	`Revenues`	$3.51M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$8.43M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$9.53M	USD	1 Quarter
Salaries and payroll-related costs	`LaborAndRelatedExpense`	$3.99M	USD	1 Quarter
Salaries and payroll-related costs	`LaborAndRelatedExpense`	$4.28M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.67M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.85M	USD	1 Quarter
Stock-based compensation	`AllocatedShareBasedCompensationExpense`	$2.09M	USD	1 Quarter
Stock-based compensation	`AllocatedShareBasedCompensationExpense`	$2.42M	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$1.14M	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$1.19M	USD	1 Quarter
TOTAL OPERATING EXPENSES	`OperatingExpenses`	$19.27M	USD	1 Quarter
TOTAL OPERATING EXPENSES	`OperatingExpenses`	$17.32M	USD	1 Quarter
OPERATING LOSS	`OperatingIncomeLoss`	$-13.81M	USD	1 Quarter
OPERATING LOSS	`OperatingIncomeLoss`	$-14.90M	USD	1 Quarter
Interest income (expense), net	`InterestIncomeExpenseNonoperatingNet`	$163.73K	USD	1 Quarter
Interest income (expense), net	`InterestIncomeExpenseNonoperatingNet`	$25.15K	USD	1 Quarter
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$1.48M	USD	1 Quarter
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$450.74K	USD	1 Quarter
Other income (expense)	`OtherNonoperatingIncomeExpense`	$1.31M	USD	1 Quarter
TOTAL OTHER INCOME (EXPENSE)	`NonoperatingIncomeExpense`	$2.82M	USD	1 Quarter
TOTAL OTHER INCOME (EXPENSE)	`NonoperatingIncomeExpense`	$614.47K	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-13.20M	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-12.09M	USD	1 Quarter
NET LOSS	`ProfitLoss`	$-12.09M	USD	1 Quarter
NET LOSS	`ProfitLoss`	$-13.20M	USD	1 Quarter
NET LOSS PER SHARE - BASIC & DILUTED	`EarningsPerShareBasicAndDiluted`	$-0.17	USD	1 Quarter
NET LOSS PER SHARE - BASIC & DILUTED	`EarningsPerShareBasicAndDiluted`	$-0.18	USD	1 Quarter
Weighted average shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	74.83M	shares	1 Quarter
Weighted average shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	71.44M	shares	1 Quarter
Foreign Currency Translation Adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-9.53K	USD	1 Quarter
Foreign Currency Translation Adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-192.61K	USD	1 Quarter
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-13.21M	USD	1 Quarter
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-12.28M	USD	1 Quarter

Cash Flow Statement 49 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-12.09M	USD	1 Quarter
Net loss	`ProfitLoss`	$-13.20M	USD	1 Quarter
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$1.48M	USD	1 Quarter
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$450.74K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$2.42M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$2.09M	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$1.14M	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$1.19M	USD	1 Quarter
Amortization/(accretion) of note premiums	`InvestmentIncomeNetAmortizationOfDiscountAndPremium`	$-107.78K	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-15.00K	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$82.13K	USD	1 Quarter
Prepaid expenses and Other Current Assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$29.22K	USD	1 Quarter
Prepaid expenses and Other Current Assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-1.03M	USD	1 Quarter
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$25.65M	USD	1 Quarter
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$-3.39M	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$1.63M	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-4.65M	USD	1 Quarter
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$-2.55M	USD	1 Quarter
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$-1.85M	USD	1 Quarter
Other	`IncreaseDecreaseInOtherOperatingLiabilities`	$43.91K	USD	1 Quarter
Other	`IncreaseDecreaseInOtherOperatingLiabilities`	$-235.47K	USD	1 Quarter
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-14.69M	USD	1 Quarter
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$10.00M	USD	1 Quarter
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$135.41K	USD	1 Quarter
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$5.30M	USD	1 Quarter
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$5.02M	USD	1 Quarter
Proceeds from sale of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$6.51M	USD	1 Quarter
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-5.30M	USD	1 Quarter
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$1.36M	USD	1 Quarter
Principal payments on notes payable	`RepaymentsOfNotesPayable`	$47.28K	USD	1 Quarter
Principal payments on notes payable	`RepaymentsOfNotesPayable`	$197.79K	USD	1 Quarter
Payments of taxes for net share settled restricted stock unit issuances	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$417.14K	USD	1 Quarter
Proceeds from the exercises of warrants and stock options	`ProceedsFromExercisesOfWarrantsAndStockOptions`	$224.08K	USD	1 Quarter
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$12.50M	USD	1 Quarter
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$12.04M	USD	1 Quarter
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$26.29K	USD	1 Quarter
NET INCREASE (DECREASE) IN CASH	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-13.31M	USD	1 Quarter
NET INCREASE (DECREASE) IN CASH	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$16.74M	USD	1 Quarter
CASH AT BEGINNING OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$102.11M	USD	Point-in-time
CASH AT BEGINNING OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$24.84M	USD	Point-in-time
CASH AT BEGINNING OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$11.53M	USD	Point-in-time
CASH AT BEGINNING OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$85.37M	USD	Point-in-time
CASH AT END OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$102.11M	USD	Point-in-time
CASH AT END OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$24.84M	USD	Point-in-time
CASH AT END OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$11.53M	USD	Point-in-time
CASH AT END OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$85.37M	USD	Point-in-time
Interest Paid	`InterestPaid`	$44.72K	USD	1 Quarter
Interest Paid	`InterestPaid`	$48.20K	USD	1 Quarter
Property and Equipment expenditures included in accounts payable and accrued expenses	`PropertyAndEquipmentExpendituresIncludedInAccountsPayableAndAccruedExpenses`	$1.04M	USD	1 Quarter

Stockholders Equity 10 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance, Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$80.87M	USD	Point-in-time
Beginning Balance, Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$70.20M	USD	Point-in-time
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$2.09M	USD	1 Quarter
Exercise of warrants, Amount	`StockIssuedDuringPeriodValueExerciseOfWarrants`	$448.01K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-9.53K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-192.61K	USD	1 Quarter
Net loss	`ProfitLoss`	$-12.09M	USD	1 Quarter
Net loss	`ProfitLoss`	$-13.20M	USD	1 Quarter
Ending Balance, Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$80.87M	USD	Point-in-time
Ending Balance, Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$70.20M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.